Lista de obras -

8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes

artículo científico publicado en 2005

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

artículo científico publicado en 2015

Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study).

artículo científico publicado en 2010

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study

artículo científico publicado en 2015

Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes.

artículo científico publicado en 2002

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

artículo científico publicado en 2006

Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.

artículo científico publicado en 2004

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

artículo científico publicado en 2010

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.

artículo científico publicado en 2017

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

artículo científico publicado en 2018

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

artículo científico publicado en 2017

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

artículo científico publicado en 2018

Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).

artículo científico publicado en 2018

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

artículo científico publicado en 2015

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib

artículo científico publicado en 2017

HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia

artículo científico publicado en 2017

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

artículo científico publicado en 2011

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

artículo científico publicado en 2018

Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study

artículo científico publicado en 2003

High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2006

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study

artículos científicos

Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature ⬇️

artículo científico publicado en 2005

JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study.

artículo científico publicado en 2010

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

artículo científico publicado en 2008

More concern about transfusion requirement when evaluating quality of life in anemic patients.

artículo científico publicado en 2002

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

artículo científico publicado en 2009

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

artículo científico publicado en 2012

Performances of XA1.3 ASIC chip for the SuperAGILE experiment on board of AGILE

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

artículo científico publicado en 2015

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

scholarly article by Anna Lucia Fedullo et al published February 2019 in Haematologica

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

artículo científico publicado en 2018

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia

artículo científico publicado en 2014

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

artículo científico publicado en 2016

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

artículo científico publicado en 2016

Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor

artículo científico publicado en 2017

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

artículo científico publicado en 2016

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia

artículo científico publicado en 2018

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods

artículo científico publicado en 2008

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

artículo científico publicado en 2009

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

artículo científico publicado en 2010

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Lista de obras de

8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study).

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study

Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes.

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib

HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study

High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study

Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature ⬇️

JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

More concern about transfusion requirement when evaluating quality of life in anemic patients.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Performances of XA1.3 ASIC chip for the SuperAGILE experiment on board of AGILE

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response